Ocular Therapeutix Reports Exit/Disposal Costs
Ticker: OCUL · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1.0, $2.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, costs
Related Tickers: OCUL
TL;DR
OCUL is booking costs for exiting/disposing of something. Keep an eye on the financials.
AI Summary
Ocular Therapeutix, Inc. reported on May 29, 2024, that it is incurring costs associated with exit or disposal activities. The company, incorporated in Delaware, is headquartered at 15 Crosby Drive, Bedford, MA 01730, with a principal executive office phone number of (781) 357-4000.
Why It Matters
This filing indicates the company is undergoing restructuring or divesting certain assets, which could impact future operations and financial performance.
Risk Assessment
Risk Level: medium — Disposal activities can signal financial distress or strategic shifts that carry inherent business risks.
Key Players & Entities
- Ocular Therapeutix, Inc. (company) — Filer
- May 29, 2024 (date) — Earliest event reported
- 15 Crosby Drive, Bedford, MA 01730 (location) — Principal Executive Offices
- (781) 357-4000 (phone_number) — Company's telephone number
FAQ
What specific activities are associated with the exit or disposal?
The filing states that the company is incurring costs associated with exit or disposal activities, but does not specify the nature of these activities.
When did these exit or disposal activities begin?
The earliest event reported in relation to these activities was May 29, 2024.
What is the exact nature of the costs being incurred?
The filing does not provide specific details on the types of costs associated with the exit or disposal activities.
Is this filing related to a specific product or division being divested?
The filing does not specify which product or division is subject to the exit or disposal activities.
What is the expected financial impact of these disposal costs?
The filing does not quantify the expected financial impact of these costs.
Filing Stats: 980 words · 4 min read · ~3 pages · Grade level 17.6 · Accepted 2024-06-03 09:15:16
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq
- $1.0 — al restructuring costs of approximately $1.0 to $2.0 million, which includes garden
- $2.0 m — ucturing costs of approximately $1.0 to $2.0 million, which includes garden leave, sev
Filing Documents
- tm2416236d1_8k.htm (8-K) — 26KB
- 0001104659-24-067544.txt ( ) — 195KB
- ocul-20240529.xsd (EX-101.SCH) — 3KB
- ocul-20240529_lab.xml (EX-101.LAB) — 33KB
- ocul-20240529_pre.xml (EX-101.PRE) — 22KB
- tm2416236d1_8k_htm.xml (XML) — 3KB
05
Item 2.05 Costs Associated With Exit or Disposal Activities. On May 29, 2024, the board of directors (the "Board") of Ocular Therapeutix, Inc. (the "Company") approved a strategic reduction in force to eliminate 37 full-time employees of the Company, primarily in research and development and technical operations and representing approximately 13% of the Company's workforce, as part of an initiative to prioritize Company resources on the clinical development of AXPAXLI (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration. The Company currently expects to substantially complete the reduction in force and to record the related restructuring charges in the second quarter of 2024. The Company anticipates incurring total restructuring costs of approximately $1.0 to $2.0 million, which includes garden leave, severance benefits and related costs and which are expected to result in cash expenditures during the second and third quarters of 2024. The Company is continuing to review its business plan and the potential impact of the reduction in force and is unable to estimate any additional restructuring costs or charges at this time. If the Company subsequently determines that it will incur additional significant costs and restructuring charges, it will amend this Current Report on Form 8-K to disclose such information. Cautionary Note on Forward-Looking Statements Any statements in this Current Report on Form 8-K about future expectations, plans, and prospects for the Company, including the impact of and restructuring costs and potential future savings associated with the Company's reduction in force; the development and regulatory status of the Company's product candidates; the Company's cash runway and the sufficiency of the Company's cash resources; and other statements containing the words "anticipate", "believe", "estimate", "expect", "intend", "goal", "may", "might", "plan", "predict", "project", "target
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: June 3, 2024 By: /s/ Donald Notman Donald Notman Chief Financial Officer